Management

Donald J. McCaffreyPresident and Chief Executive Officer

Donald McCaffrey is President, & CEO of Zenith Epigenetics Corp. Don has 34 years of experience in business management, capital markets and drug discovery & development and in the process has raised over $200 million in drug development capital. Don’s expertise in corporate operations has attracted a strong international team of R&D experts to Zenith Epigenetics.

Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Mount Royal University, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program. In 2008 Don attended the prestigious World Economic Forum in Davos Switzerland as the CEO recipient of a Pioneer Technology of the year award winner and returned to the 2009 WEF event as an invited guest speaker.

Dr. Norman C.W. Wong, M.D., FRCPChief Scientific Officer

Norman Wong is Chief Scientific Officer at Zenith Epigenetics. Dr. Wong's research interest focuses on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus.  These topics of interest involved studies of chromatin structure, gene regulation and transcription factors which are major components of epigenetics.  His clinical interest encompasses patients with thyroid disease including thyroid cancer or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression using inhibition of BET-proteins that play important roles in epigenetics.

Dr. Wong keeps active in the academic community by participating in speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

A. Brad Cann, CAChief Financial Officer

Brad has more than 18 years of financial and business experience. Between 2004 and 2009, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust (REIT), a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions. 

Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.

Dr. Henrik C. Hansen, Ph.D.Vice President of Intellectual Property & Technology Development

Dr. Hansen is the VP of Intellectual Property & Technology Development at Zenith. Henrik is responsible for the intellectual property portfolio, and he assumes a leading role in the implementation of corporate objectives by interfacing with all parts of the corporation; monitors resource needs and ensures that appropriate resources are available and aligned with corporate goals. He provides insight to achieve the right balance between science, business, and financial objectives, by applying a strong understanding of all aspects of the corporation.

Henrik has more than 13 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry, carbohydrate chemistry, process development, and manufacturing of drug substances and drug products under Current Good Manufacturing Practices (cGMPs) for clinical use.

Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as an inventor of 9 patent families.

Dr. Lida Antonian, Ph.D.Executive Director, Pharmacokinetics & Drug Metabolism

Dr. Lida Antonian joined Zenith in 2013 with 30 years of broad discovery and drug development experience.  She is leading our activities in regulated and discovery pharmacokinetics and drug metabolism. Her expertise extends across small molecule discovery and development and clinical development of biotherapeutics. Lida has held senior management and scientific appointments at Merck, SUGEN, Nektar, Genelabs, Bristol-Myers Squibb, and Jennerex Biotherapeutics. Lida also was an assistant professor at Weill Cornell Medical College before joining the pharmaceutical industry. Lida’s past involvement in the development of EPRINEX, SUTENT, NKTR-102, and PEG-Interferon Lamda will provide tactical guidance for developing first-in-class BET inhibitors.

Lida is a co-principal at BioTeknowledge, Inc., a San Francisco based consultancy firm. She has authored more than ninety peer-reviewed scientific publications, oral and poster presentations. Lida is an active volunteer with the Alzheimer’s Association of Northern California in public policy advocacy and through art therapy she enriches the lives of those with Alzheimer’s dementia. 

Lida earned her undergraduate degree in chemistry from City College of New York and doctorate in chemistry from New York University. 

Dr. Ravi Jahagirdar, DVM, MS.Senior Director of Pharmacology

Ravi is the Senior Director of Pharmacology. Ravi has a strong background in animal, lipid/lipoprotein physiology and manages all discovery in vivo pharmacology related to autoimmune and oncology programs at Zenith.

Ravi has over 17 years of experience from both academia and industry in in-vivo pharmacology, animal physiology, drug discovery, early toxicology and pharmacokinetic studies, basic research, assay development and high throughput screening. He has been successful in recruiting scientists, building departments and managing projects from early discovery to pre-clinical development and business collaborations. 

Ravi completed his Doctor of Veterinary Medicine in Bangalore, MS in Molecular Biology/Microbiology at Health Sciences Center (MUN, Newfoundland) and followed with basic research on understanding toxin secretion in gram negative bacteria in relationship to ABC proteins during his tenure at University of Regina. Ravi’s research has been published in many peer reviewed journals and has co-authored a text book chapter and has numerous abstract presentations.  

Dr. Kevin G. McLure, Ph.D.Senior Director of Translational Biology

Dr. McLure oversees the biology research group as the Senior Director of Translational Biology. Kevin’s responsibility for biology research encompasses mechanism of action, lead discovery and biomarkers in oncology, autoimmune and other programs. Kevin directs internal programs and manages external research collaborations. He has more than 15 years of experience in academia and industry, basic research and drug discovery. His areas of expertise include chromatin structure and transcriptional regulation, molecular oncology and basic cancer research, biochemistry, assay development & validation.

Kevin completed his PhD in Molecular Oncology at the University of Calgary with a focus on cancer therapeutic and metabolic regulation of p53 and chromatin in DNA damage responses at St. Jude Children’s Research Hospital (Memphis, TN). He has authored and co-authored more than 25 publications and meeting abstracts and is listed as an inventor of 5 patents.